$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914036063 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$5.300M	$3.500M
YoY Change	-30.95%	35.9%	2.94%
% of Gross Profit
Research & Development	$18.80M	$17.58M	$19.98M
YoY Change	5.17%	7.34%	39.23%
% of Gross Profit
Depreciation & Amortization	$170.0K	$168.0K	$150.0K
YoY Change	70.0%	68.0%	25.0%
% of Gross Profit
Operating Expenses	$21.70M	$22.91M	$23.44M
YoY Change	-1.65%	13.08%	32.43%
Operating Profit		-$22.91M	-$23.44M
YoY Change		13.08%	32.43%
Interest Expense	-$600.0K	-$650.0K	-$718.0K
YoY Change	-17.13%	38.3%	70.95%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$22.30M	-$23.60M	-$24.20M
YoY Change	-2.19%	14.01%	33.7%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$22.30M	-$23.60M	-$24.20M
YoY Change	-2.19%	14.01%	33.7%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.259M	-$9.833M	-$11.00M
COMMON SHARES
Basic Shares Outstanding	93.27M shares	85.44M shares	69.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$112.1M	$78.80M	$91.50M
YoY Change	59.69%	-12.83%	-9.05%
Cash & Equivalents	$96.80M	$52.03M	$48.49M
Short-Term Investments	$15.20M	$26.80M	$43.00M
Other Short-Term Assets	$2.300M	$1.600M	$800.0K
YoY Change	43.75%	6.67%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$114.3M	$80.39M	$92.24M
YoY Change	59.1%	-12.49%	-9.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.300M	$1.408M	$1.553M
YoY Change	-19.75%	4.3%	32.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$384.0K	$1.409M
YoY Change	-13.79%	-20.17%	207.64%
Total Long-Term Assets	$1.600M	$1.792M	$2.962M
YoY Change	-23.22%	-2.13%	81.5%
TOTAL ASSETS
Total Short-Term Assets	$114.3M	$80.39M	$92.24M
Total Long-Term Assets	$1.600M	$1.792M	$2.962M
Total Assets	$115.9M	$82.18M	$95.20M
YoY Change	56.78%	-12.29%	-7.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.200M	$5.810M	$6.589M
YoY Change	-0.42%	1.59%	16.39%
Accrued Expenses	$18.20M	$17.30M	$16.10M
YoY Change	91.58%	124.68%	62.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.200M	$9.300M	$9.500M
YoY Change	73.58%	200.0%	20.25%
Total Short-Term Liabilities	$32.70M	$32.37M	$32.21M
YoY Change	62.92%	95.55%	37.13%
LONG-TERM LIABILITIES
Long-Term Debt	$9.300M	$11.60M	$13.90M
YoY Change	-49.46%	-43.41%	208.89%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$9.300M	$11.60M	$13.91M
YoY Change	-49.5%	-43.56%	211.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.70M	$32.37M	$32.21M
Total Long-Term Liabilities	$9.300M	$11.60M	$13.91M
Total Liabilities	$41.90M	$43.96M	$46.11M
YoY Change	8.87%	18.5%	64.97%
SHAREHOLDERS EQUITY
Retained Earnings		-$575.0M	-$551.4M
YoY Change			19.56%
Common Stock		$613.2M	$600.5M
YoY Change		13.86%	11.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.00M	$38.22M	$49.09M
YoY Change
Total Liabilities & Shareholders Equity	$115.9M	$82.18M	$95.20M
YoY Change	56.78%	-12.29%	-7.59%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q4
OPERATING ACTIVITIES
Net Income	-$22.30M	-$23.60M	-$24.20M
YoY Change	-2.19%	14.01%	33.7%
Depreciation, Depletion And Amortization	$170.0K	$168.0K	$150.0K
YoY Change	70.0%	68.0%	25.0%
Cash From Operating Activities	-$20.87M	-$20.27M	-$18.69M
YoY Change	4.77%	-8.73%	49.16%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$23.00K	-$80.00K
YoY Change	-92.31%	-91.67%	-11.11%
Acquisitions
YoY Change
Other Investing Activities	$11.50M	$16.22M	-$15.06M
YoY Change	-39.51%	-144.63%	-328.18%
Cash From Investing Activities	$11.48M	$16.20M	-$15.15M
YoY Change	-38.35%	-144.24%	-332.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$10.12M
YoY Change		868.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	54.17M	7.620M	56.85M
YoY Change	45041.67%	-37.95%	-2.12%
NET CHANGE
Cash From Operating Activities	-20.87M	-20.27M	-18.69M
Cash From Investing Activities	11.48M	16.20M	-15.15M
Cash From Financing Activities	54.17M	7.620M	56.85M
Net Change In Cash	44.78M	3.550M	23.01M
YoY Change	-3894.92%	-107.63%	-55.81%
FREE CASH FLOW
Cash From Operating Activities	-$20.87M	-$20.27M	-$18.69M
Capital Expenditures	-$30.00K	$23.00K	-$80.00K
Free Cash Flow	-$20.84M	-$20.29M	-$18.61M
YoY Change	6.71%	-9.75%	49.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-574969000	USD
CY2013Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	18000	USD
CY2013Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	1000	USD
CY2014Q1	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	5000	USD
CY2014Q1	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	1000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21853000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22029000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20445000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20476000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1408000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1553000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2586000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1216000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16689000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y25D
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2162000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3137000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1621000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1585000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	982000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	996000	USD
CY2014Q1	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	4765000	USD
CY2013Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	5718000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6961000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9214000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4606000	USD
CY2014Q1	us-gaap	Secured Debt SecuredDebt	20781000	USD
CY2014Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	9261000	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	11520000	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">(1) Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.35in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.35in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.35in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company may require significant additional funds earlier than it currently expects in order to conduct additional clinical trials and continue to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, significantly modify or terminate its research and development programs or reduce its planned commercialization efforts.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93274506	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52034000	USD
CY2014Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	26753000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1605000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	80392000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	384000	USD
CY2014Q1	us-gaap	Assets Assets	82184000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5810000	USD
CY2014Q1	snta	Accrued Contract Research Costs AccruedContractResearchCosts	12488000	USD
CY2014Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	41000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	32365000	USD
CY2014Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	75000	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11595000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	43960000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	613180000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	38224000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82184000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48490000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	42986000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	765000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	92241000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1409000	USD
CY2013Q4	us-gaap	Assets Assets	95203000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6589000	USD
CY2013Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	10407000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	42000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	9451000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32207000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	85000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	13820000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13905000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	46112000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	600477000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-551412000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	49091000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95203000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	11000	USD
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87593991	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87593991	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85232506	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85232506	shares
CY2014Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17583000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5324000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	22907000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22907000	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-650000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23557000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85438127	shares
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16380000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3878000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	20258000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20258000	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-470000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20728000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68991371	shares
CY2014Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23570000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20723000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2586000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-153000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-32000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-780000	USD
CY2014Q1	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	2081000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-953000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20270000	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	3548000	USD
CY2014Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	19768000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	16197000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10118000	USD
CY2014Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2490000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7617000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3544000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	560000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1216000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	689000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	23000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	58000	USD
CY2013Q1	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	140000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2288000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22214000	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	55290000	USD
CY2013Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	18950000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	276000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-36616000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1045000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	13210000	USD
CY2013Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1972000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12280000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-46550000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	789000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34962000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81512000	USD
CY2014Q1	snta	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD

Files In Submission

Name	View Source	Status
0001104659-14-036063-index-headers.html	Edgar Link	pending
0001104659-14-036063-index.html	Edgar Link	pending
0001104659-14-036063.txt	Edgar Link	pending
0001104659-14-036063-xbrl.zip	Edgar Link	pending
a14-9683_110q.htm	Edgar Link	pending
a14-9683_1ex10d2.htm	Edgar Link	pending
a14-9683_1ex10d3.htm	Edgar Link	pending
a14-9683_1ex10d4.htm	Edgar Link	pending
a14-9683_1ex31d1.htm	Edgar Link	pending
a14-9683_1ex31d2.htm	Edgar Link	pending
a14-9683_1ex32d1.htm	Edgar Link	pending
a14-9683_1ex5d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g96831fti001.jpg	Edgar Link	pending
g96831fti002.jpg	Edgar Link	pending
g96831fvi001.jpg	Edgar Link	pending
g96831kei001.jpg	Edgar Link	pending
g96831kui001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20140331.xml	Edgar Link	completed
snta-20140331.xsd	Edgar Link	pending
snta-20140331_cal.xml	Edgar Link	unprocessable
snta-20140331_def.xml	Edgar Link	unprocessable
snta-20140331_lab.xml	Edgar Link	unprocessable
snta-20140331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

2014 Q2 Form 10-Q Financial Statement

#000110465914036063 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL Madrigal Pharmaceuticals Inc Stock $mdgl

2014 Q2 Form 10-Q Financial Statement

#000110465914036063 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl